Substituted indolines as tyrosine kinase inhibitors

US8207179B2 · kind B2 · utility

Assignee

• Boehringer Ingelheim International GmbH · DE

Inventors

• Harald Engelhardt · Ebreichsdorf, AT
• Bodo Betzemeier · Biberach an der Riß, DE
• Guido Boehmelt · Ingelheim am Rhein, DE
• Ulrich Guertler · Wien, AT
• Thomas Karner · Wien, AT
• Oliver Kraemer · Wien, AT
• Daniel Kuhn · Düsseldorf, DE
• Jens Juergen Quant · Guntramsdorf, AT
• Ulrich Reiser · Wien, AT
• Otmar Schaaf · Wien, AT
• Flavio Solca · Wien, AT
• Heinz Stadtmueller · Wien, AT
• Ulrike Tontsch-Grunt · Baden, AT
• Matthias Treu · Wien, AT
• Stephan Karl Zahn · Wien, AT

Key dates

• Filing date: Jun 9, 2008
• Grant date: Jun 26, 2012
• Expiry date: Jun 29, 2028

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D513/04
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

The present invention encompasses compounds of general Formula (1) wherein R2, R3, Q, W, X, Y and Z are defined as in claim 1, which are suitable for the treatment of diseases characterized by excessive or abnormal cell proliferation, and the use thereof for preparing a medicament having the above-mentioned properties.